{
    "Trade/Device Name(s)": [
        "FREND\u2122 PSA Plus"
    ],
    "Submitter Information": "NanoEnTek, Inc.",
    "510(k) Number": "K162378",
    "Predicate Device Reference 510(k) Number(s)": [
        "K124056"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTJ"
    ],
    "Summary Letter Date": "April 18, 2017",
    "Summary Letter Received Date": "April 19, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System",
        "Prostate-Specific Antigen (PSA) for Management of Prostate Cancers"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Total Prostate Specific Antigen (PSA)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "K3-EDTA plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "FREND\u2122 System"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay"
    ],
    "Methodologies": [
        "Quantitative immunoassay",
        "Micro-fluidics lateral flow",
        "Laser-induced fluorescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Cartridge",
        "Code Chip",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for FREND\u2122 PSA Plus quantitative fluorescence immunoassay to measure total PSA for prostate cancer management using the FREND\u2122 System",
    "Indications for Use Summary": "Quantitative measurement of total PSA in human serum, lithium heparinized plasma, and K3-EDTA plasma using the FREND\u2122 System, indicated for serial measurement as an aid in management of patients with prostate cancer",
    "fda_folder": "Immunology"
}